Acquisition by Stelzer Laurie of 50000 shares of Aeglea Bio subject to Rule 16b-3
AGLEDelisted Stock | USD 0.59 0.01 1.72% |
About 54% of Aeglea Bio's shareholders are presently thinking to get in. The analysis of current outlook of investing in Aeglea Bio Therapeutics suggests that some traders are interested regarding Aeglea Bio's prospects. The current market sentiment, together with Aeglea Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Aeglea Bio Therapeutics stock news signals to limit their universe of possible portfolio assets.
Aeglea |
Filed transaction by Aeglea Biotherapeutics In director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Aeglea Bio Fundamental Analysis
We analyze Aeglea Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeglea Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeglea Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Aeglea Bio is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Aeglea Bio Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aeglea Bio stock to make a market-neutral strategy. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics with similar companies.
Peers
Aeglea Bio Related Equities
BPTH | Bio Path | 15.62 | ||||
DSGN | Design Therapeutics | 4.23 | ||||
IKNA | Ikena Oncology | 1.80 | ||||
CING | Cingulate | 1.17 | ||||
EWTX | Edgewise Therapeutics | 1.15 | ||||
ALRN | Aileron Therapeutics | 0.93 | ||||
NUVB | Nuvation Bio | 1.11 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
CTMX | CytomX Therapeutics | 2.48 | ||||
SNTI | Senti Biosciences | 2.49 | ||||
XLO | Xilio Development | 2.80 | ||||
BNTC | Benitec Biopharma | 3.61 | ||||
ASMB | Assembly Biosciences | 6.46 | ||||
TIL | Instil Bio | 7.12 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Stocks Directory Find actively traded stocks across global markets |